Overview


According to FutureWise analysis the market for antineoplastic drugs in 2023 is US$ 134.66 billion, and is expected to reach US$ 338.70 billion by 2031 at a CAGR of 12.22%.

Antineoplastic drugs, commonly called chemotherapy or anticancer drugs, are a class of medications designed to combat the growth, spread, and proliferation of cancerous cells within the body. These drugs are a cornerstone of cancer treatment and target various types of cancer, including solid tumors and hematological malignancies. Antineoplastic drugs disrupt the cell cycle or interfere with the cellular processes that allow cancer cells to multiply uncontrollably. They exert their effects through different mechanisms, such as inhibiting DNA replication, interfering with cell division, or impeding the formation of new blood vessels that supply nutrients to tumors. Unlike many other medications localized to a specific body area, these drugs are typically administered through various routes, including oral ingestion, intravenous infusion, or topical applications. This systemic approach allows them to reach cancer cells that may have spread to different body parts, a crucial aspect in treating metastatic cancers.

The selection of specific antineoplastic drugs and the dosage and treatment regimen are highly individualized and depend on factors like the type and stage of cancer, the patient's overall health, and any concurrent medical conditions. Often, combinations of different drugs with distinct mechanisms of action are used to maximize efficacy and minimize the development of drug resistance.

FutureWise Market Research has published a report that provides an insightful analysis of Antineoplastic Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antineoplastic Drugs Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Baxter Healthcare
  • Boehringer Ingelheim
  • Aspen
  • Bayer AG
  • Teva Pharmaceutical Industries
  • Johnson and Johnson
  • MercCo.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antineoplastic Drugs Market:

  • In March 2021, ImmunityBio, Inc. and NantKwest, Inc. merged to establish a leading late-stage cell therapy and immunotherapy company, explicitly focusing on oncology and infectious diseases. The combined entity is now known as Immunity Bio, Inc. and is publicly listed on NASDAQ under the IBRX ticker.

Globally, there is a surge in the prevalence of cancer, driven by factors such as aging populations, lifestyle choices, and environmental exposures. This increasing incidence provides a substantial demand for antineoplastic drugs, a vital component of cancer treatment. Ever-growing technological advancement with ongoing research and development efforts have led to the discovering of new and more effective antineoplastic drugs. The emergence of personalized medicine, which tailors treatment plans based on individual patient characteristics and tumor profiles, has led to more precise and effective use of antineoplastic drugs. This approach maximizes therapeutic benefits while minimizing potential side effects. Growing healthcare expenditure, especially in developed countries, allows for greater accessibility to advanced cancer treatments, including antineoplastic drugs. With the rise in the geriatric population, the incidence of cancer in older individuals is expected to rise. Since cancer is more prevalent in older age groups, there will be a greater need for antineoplastic drugs to manage and treat these cases.
 
Antineoplastic drugs target cancer cells and affect healthy, rapidly dividing cells in the body. This can lead to side effects such as bone marrow suppression, nausea, and hair loss. The potential for these adverse effects can limit the use of some drugs and impact patient adherence to treatment. The emergence of alternative treatment modalities, such as targeted therapies, immunotherapies, and gene therapies, provides additional options for cancer patients. Depending on the type of cancer and individual patient characteristics, these alternative approaches may be preferred over traditional chemotherapy.

By Product Type

  • Chemotherapeutic Agents
  • Biological/Immunotherapeutic Agents
  • Personalized Medicine

By Application

  • Hospitals
  • Clinics
  • Cancer Rehabilitation Centers
  • Ambulatory Surgical Centers

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to rise in the cancer cases, robust healthcare infrastructure, the prominent presence of key industry players, a surge in chronic disease cases, and heightened research endeavors in this geographical region. Conversely, the Asia-Pacific region is poised for substantial expansion in the forecast period due to the rapid adoption of evolving lifestyles, an upswing in research initiatives, access to extensive untapped markets, a sizable population base, and an escalating demand for high-quality healthcare services.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antineoplastic Drugs Market By Product Type, By Application and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record evaluate and analyze competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction

    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data From Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antineoplastic Drugs Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards And Compliances

  • 5.   Market Overview

    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.   Global Antineoplastic Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antineoplastic Drugs Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Chemotherapeutic Agents
        2. Biological/Immunotherapeutic Agents
        3. Personalized Medicine

  • 8.   Global Antineoplastic Drugs Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospitals
        2. Clinics
        3. Cancer Rehabilitation Centers
        4. Ambulatory Surgical Centers

  • 9.   North America Antineoplastic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.  Latin America Infusion Consumables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.  Europe Antineoplastic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe

  • 12.  Asia Pacific Antineoplastic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) with expected regulatory needs

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

    •   1. Hoffmann-La Roche
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Amgen
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol-Myers Squibb
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Baxter Healthcare
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Boehringer Ingelheim
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Aspen
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Teva Pharmaceutical Industries
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Johnson and Johnson
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. MercCo.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client

    •   


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11